

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Insulin lispro (Humalog)

Notes:

- Quantity Limits: No
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- ^ insulinopenia is defined as a fasting c-peptide level of 0.88 ng/mL or less with a concurrent glucose of 70-225 mg/dL OR in patients with renal insufficiency (creatinine clearance of 50 mL/min or less), a fasting c-peptide level of 1.6 ng/mL or less with a concurrent glucose of 70-225 mg/dL.

Initiation (new start) criteria: Non-formulary **insulin lispro (Humalog) or its unbranded biologic** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of type 2 diabetes mellitus with a documented allergy or intolerance* to insulin aspart, or its biosimilar insulin aspart-xjhz (Kirsty), and regular insulin

-OR-

- Diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus with insulinopenia^ with a documented allergy or intolerance* to insulin aspart, or its biosimilar insulin aspart-xjhz (Kirsty)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **insulin lispro (Humalog) or its unbranded biologic** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of type 2 diabetes mellitus with a documented allergy or intolerance* to insulin aspart, or its biosimilar insulin aspart-xjhz (Kirsty), and regular insulin

-OR-

- Diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus with insulinopenia^ with a documented allergy or intolerance* to insulin aspart, or its biosimilar insulin aspart-xjhz (Kirsty)